<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Left ventricular thrombus after acute myocardial infarction</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Left ventricular thrombus after acute myocardial infarction</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Left ventricular thrombus after acute myocardial infarction</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory YH Lip, MD, FRCPE, FESC, FACC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nikolaus Sarafoff, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Warren J Manning, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Todd F Dardas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 08, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Left ventricular (LV) thrombus may develop after acute myocardial infarction (MI) and occurs most often with a large, anterior ST-elevation MI (STEMI). However, the use of reperfusion therapies, including percutaneous coronary intervention and fibrinolysis, has significantly reduced the risk. LV thrombus can lead to arterial embolic complications such as stroke. Patients with LV thrombus or those at high risk for development of this complication should receive anticoagulation for at least three months.</p><p>This topic will discuss LV thrombus in detail. Other potential causes of arterial emboli originating in the heart are presented elsewhere:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/8213.html" rel="external">"Clinical features and diagnosis of acute lower extremity ischemia", section on 'Arterial embolism'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1119.html" rel="external">"Overview of secondary prevention for specific causes of ischemic stroke and transient ischemic attack", section on 'Cardiogenic embolism'</a>.)</p><p></p><p class="headingAnchor" id="H3248365798"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>LV thrombus is most often seen in patients with large, anterior ST-elevation MI with anteroapical aneurysm. In most cases, these infarcts occur in the distribution of the left anterior descending coronary artery [<a href="#rid1">1</a>]. These anteroapical infarcts have large areas of poorly contracting LV muscle; adjacent intracavitary blood movement is sluggish (stasis) compared with normal areas. This relative stasis of blood is thought to increase the risk of thrombus formation. Many, but not all, of these patients will have an LV apical aneurysm with akinesis or dyskinesis. In most cases, thrombus is located within or adjacent to the LV apex [<a href="#rid1">1</a>] but can also occur with large basal inferolateral infarctions/aneurysms. Contact of blood with the fibrous tissue in the aneurysm rather than normal endocardium is also thought to trigger clot formation. </p><p class="headingAnchor" id="H3601743910"><span class="h1">AT-RISK PATIENTS</span><span class="headingEndMark"> — </span>Patients with one or more of the following are at risk for the development of LV thrombus. However, we do not routinely anticoagulate patients at risk in the absence of documented LV thrombus.</p><p class="bulletIndent1"><span class="glyph">●</span>Anterior ST-elevation MI by electrocardiographic criteria. (See  <a class="medical medical_review" href="/z/d/html/2095.html" rel="external">"Electrocardiogram in the diagnosis of myocardial ischemia and infarction", section on 'Anterior, lateral, and apical MI'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Left anterior descending coronary artery infarct (especially proximal left anterior descending coronary artery infarct).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Large infarction defined as a LV ejection fraction (LVEF) &lt;30 percent. Many, but not all, of these patients will have an LV aneurysm. (See  <a class="medical medical_review" href="/z/d/html/60.html" rel="external">"Left ventricular aneurysm and pseudoaneurysm following acute myocardial infarction", section on 'Left ventricular aneurysm'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Long delay between onset of symptoms and reperfusion (more than four to six hours) due to the increased risk for an LV aneurysm due to more extensive infarction/systolic dysfunction.</p><p></p><p class="headingAnchor" id="H141352237"><span class="h1">INCIDENCE</span><span class="headingEndMark"> — </span>Over the past 30 years, the incidence of LV thrombus has decreased as the frequency of early reperfusion therapies has increased. The likely mechanism is that early reperfusion, compared with no or late reperfusion, leads to smaller infarction [<a href="#rid1">1-12</a>]. Its impact may be greatest in patients with anterior infarctions, which tend to be larger than infarcts at other locations. (See <a class="local">'Pathophysiology'</a> above.)</p><p>The incidence of LV thrombi in the prereperfusion era was reported to be as high as 40 percent in patients with anterior infarction [<a href="#rid4">4,7</a>]. Most thrombi developed within the first two weeks (median five to six days) after MI [<a href="#rid3">3,4,7,10,11</a>]. In a series of 30 patients with LV thrombus after an acute anterior MI, 27 percent were present at less than 24 hours, 57 percent at 48 to 72 hours, 75 percent at one week, and 96 percent at two weeks [<a href="#rid5">5</a>].</p><p>Data are more limited on the incidence of LV thrombus in the reperfusion era. In two series of ST-elevation MI (STEMI) patients treated with primary percutaneous coronary intervention, the incidence of LV thrombus was about 4 percent [<a href="#rid13">13,14</a>].</p><p>However, the true incidence of LV thrombus in the current reperfusion era may be higher than in the above studies, as reported incidence depends on the sensitivity of the diagnostic test used. Cardiovascular magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) has been shown to be considerably more sensitive than transthoracic echocardiography (TTE) with or without an intravenous endocardial border definition contrast agent. In a study of 201 STEMI patients, of whom 199 were treated with reperfusion, who were evaluated with LGE-CMR, the incidence of LV thrombus was 8 percent [<a href="#rid1">1</a>].</p><p>Finally, some of these studies may have underestimated the true incidence, as patients at high risk for LV thrombus (severe heart failure and systolic blood pressure below 100 mmHg) were excluded. (See <a class="local">'Diagnosis'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>Most patients with acute ST-elevation MI (STEMI) should undergo (noncontrast) TTE to assess LV systolic function before discharge with specific evaluation of anteroapical systolic function, aneurysm, and the presence of an LV thrombus  (<a class="graphic graphic_algorithm graphicRef116123" href="/z/d/graphic/116123.html" rel="external">algorithm 1</a>). In most patients, the diagnosis of an LV thrombus will be made using TTE  (<a class="graphic graphic_diagnosticimage graphicRef109717" href="/z/d/graphic/109717.html" rel="external">image 1</a> and <a class="graphic graphic_movie graphicRef109718" href="/z/d/graphic/109718.html" rel="external">movie 1</a>). (See <a class="local">'At-risk patients'</a> above.)</p><p>TTE performed very early after an anteroapical infarction may show an LVEF &lt;30 percent; however, repeat TTE 48 hours after reperfusion may show significant improvement in LV systolic function. (See <a class="local">'Incidence'</a> above.)</p><p>When the sonographer is screening for LV thrombus, particular attention should be paid to the LV apex (or for any aneurysm or dyskinetic segment). In addition to reporting the presence of an aneurysm and wall motion in that region, the presence or absence of thrombus should be noted in the report. TTE characteristics of LV thrombus include a mural or pedunculated echodensity often of similar acoustic properties to myocardium  (<a class="graphic graphic_movie graphicRef85959 graphicRef85958" href="/z/d/graphic/85959.html" rel="external">movie 2A-B</a>). (See  <a class="medical medical_review" href="/z/d/html/5303.html" rel="external">"Echocardiography in detection of cardiac and aortic sources of systemic embolism", section on 'Left ventricular thrombi'</a>.)</p><p>TTE image quality may be suboptimal due to conditions such as chronic pulmonary disease or obesity. Distinguishing thrombus from normal trabeculations may also be difficult. Near-field artifact may also give the appearance of apical thrombus. The sonographer should use an intravenous endocardial border definition contrast agent whenever an apical aneurysm is identified [<a href="#rid15">15,16</a>]. With contrast injection, LV thrombus appears as a filling defect within the ventricular cavity. (See  <a class="medical medical_review" href="/z/d/html/5313.html" rel="external">"Contrast echocardiography: Clinical applications", section on 'Rest echocardiography'</a>.)</p><p>In patients where there remains uncertainty regarding the presence or absence of thrombus, CMR with gadolinium contrast using a long inversion time should be considered. We consider transesophageal echocardiography (TEE) inferior to long inversion time late gadolinium enhancement (LGE) CMR for the diagnosis of LV thrombus since the apex is often not well visualized by the former test, but may be considered when CMR is not available. Contrast-enhanced cardiac computed tomography is another option.</p><p>CMR is considered the gold standard for the noninvasive diagnosis of LV thrombus. Long inversion time LGE-CMR has a greater sensitivity than TTE and a similarly high specificity for the detection of LV thrombus in an ischemic cardiomyopathy population [<a href="#rid17">17-19</a>]. However, it is not used to screen for LV thrombus in all patients with an anteroapical aneurysm due to issues of cost and availability. (See  <a class="medical medical_review" href="/z/d/html/5314.html" rel="external">"Clinical utility of cardiovascular magnetic resonance imaging"</a>.)</p><p>In a retrospective study of 160 patients with a remote prior MI who had surgical and/or pathological confirmation of the presence (48 patients [30 percent]) or absence of LV thrombus, all patients underwent nonsimultaneous preoperative LGE-CMR, TTE, and intraoperative TEE [<a href="#rid17">17</a>]. CMR was significantly more sensitive (88 versus 23 and 40 percent with TTE and TEE, respectively). All imaging modalities had specificities of 96 percent or greater.</p><p>In another study, 201 patients were evaluated with noncontrast and contrast TTE, cine-CMR, and LGE-CMR 7 to 30 days after STEMI [<a href="#rid1">1</a>]. Using LGE-CMR as the gold standard for determining the presence of absence of LV thrombus, the following findings were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>LV thrombus was present in 17 patients (8 percent).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The sensitivity of noncontrast and contrast TTE was only 35 and 64 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The specificity of noncontrast and contrast TTE was 98 and 99 percent, respectively.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Only 12 percent of patients with thrombus had a LVEF ≤30 percent, and LV aneurysm was present in only 24 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On both noncontrast and contrast TTE, a high apical wall motion score, as measure of apical dysfunction, was strongly correlated with the presence of LV thrombus.</p><p></p><p class="headingAnchor" id="H724802349"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>In addition to MI, true LV thrombus may occur in other conditions such as stress cardiomyopathy or myocarditis. However, in a patient with documented acute STEMI, the odds are in favor of the infarct being causative.</p><p class="headingAnchor" id="H2768258535"><span class="h2">Incidentally discovered LV thrombus</span><span class="headingEndMark"> — </span>An uncommon patient may present with incidentally discovered LV thrombus during a cardiac imaging study done for other reasons. We treat with oral anticoagulant (OAC) for three months and then reevaluate the thrombus. If there is evidence of thrombus resolution, we stop OAC and reevaluate with echocardiography in another three months.</p><p class="headingAnchor" id="H4133411725"><span class="h1">OUTCOMES</span><span class="headingEndMark"> — </span>Newly diagnosed LV thrombi may undergo complete resolution, partial resolution, or endothelialization. Prior to one of these end points, embolization may occur.</p><p>The risk of embolization in patients with a documented LV thrombus who are not treated with anticoagulant therapy has been reported to be 10 to 15 percent. In a series of 85 patients with LV thrombus (most of whom had a recent MI) followed for almost two years, an embolic event occurred in 11 (13 percent) of those with thrombi compared with only 2 of 91 (2 percent) in a matched control group [<a href="#rid20">20</a>]. In another study of patients with an anterior MI, the presence of an LV mural thrombus identified by noncontrast TTE increased the incidence of an embolic event (odds ratio 5.5, 95% CI 3.0-9.8) [<a href="#rid21">21</a>]. Most embolic events occur within the first three to four months [<a href="#rid2">2,5,6,20-23</a>], although some occur later [<a href="#rid20">20</a>].</p><p>Two major echocardiographic risk factors for embolization have been identified: thrombus mobility and thrombus protrusion [<a href="#rid2">2,6,20,24</a>]. In one report, embolization occurred in 22 percent of 119 patients with an LV thrombus after acute MI [<a href="#rid2">2</a>]. Free mobility of the thrombus was present in 58 percent of patients with embolization compared with 3 percent without embolization; among the 18 patients with free thrombus mobility, embolization occurred in 15 (83 percent compared with 11 percent without mobility). Protrusion of the thrombus into the LV cavity was present in 88 percent of those patients with clinical thromboembolism compared with 18 percent without; among the 40 patients with thrombus protrusion, embolization occurred in 23 (58 percent compared with 4 percent without protrusion).</p><p>An observational study of 159 patients with a confirmed LV thrombus, most of whom were anticoagulated, found the following at a median follow-up of 103 days [<a href="#rid25">25</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>A reduction of the thrombus area from baseline was observed in 76 percent, with total regression in 62 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>During a median follow-up of 632 days, death occurred in 18 percent, stroke in 13 percent, and major bleeding in 13 percent.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A LVEF ≥35 percent and anticoagulation therapy &gt;3 months were independently associated with lower rates of major adverse cardiovascular outcomes.</p><p></p><p class="headingAnchor" id="H16390947"><span class="h1">PREVENTION OF EMBOLIC EVENTS</span><span class="headingEndMark"> — </span>The following is our approach to the prevention of stroke and systemic embolic events in at-risk patients:</p><p class="bulletIndent1"><span class="glyph">●</span>In all patients being considered for anticoagulant therapy, the benefit must be weighed against the risk of bleeding. This is particularly important since many patients will be receiving treatment with one or two oral antiplatelet agents for some period of time. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Discharge to 12 months'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>We anticoagulate most MI patients with documented LV thrombus [<a href="#rid26">26</a>]. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1">Some of our contributors will consider anticoagulation in the absence of LV thrombus if apical or basal inferior akinesis/dyskinesis with aneurysm is present. This is a particularly high-risk group for the development of LV thrombus. (See <a class="local">'At-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no large prospective or direct comparison data of direct-acting oral anticoagulants (DOAC; also referred to as non-vitamin K antagonist oral anticoagulants [NOAC]) versus <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for prophylaxis for LV thrombus. We consider using DOAC rather than warfarin due to convenience and achievement of therapeutic anticoagulation so long as there is no specific indication for warfarin (eg, prosthetic heart valve).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients in whom <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> is chosen rather than DOAC, we recommend starting parenteral anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> or a low molecular weight heparin as soon as LV thrombus after acute MI is identified. The goal activated partial thromboplastin time is two to three times the control value. Parenteral anticoagulation should be continued until effective anticoagulation with warfarin (target international normalized ratio [INR] 2 to 3) has been achieved. This recommendation may need to be modified based on the specific antithrombotic requirements of patients treated with primary percutaneous coronary intervention or fibrinolytic therapy. (See  <a class="medical medical_review" href="/z/d/html/92.html" rel="external">"Acute ST-elevation myocardial infarction: Management of anticoagulation", section on 'Summary and recommendations'</a>.)</p><p></p><p class="bulletIndent1">There are no studies that have evaluated the optimal timing of parenteral anticoagulation. We believe it is reasonable to start therapy as soon as an at-risk patient is identified and to discontinue parenteral therapy when effective anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> has been achieved (INR of 2 to 3) or the diagnosis has been excluded. Early studies of patients treated with warfarin found that anticoagulation with heparin, if started early and continued for more than 48 hours, lowers the risk of thrombus formation [<a href="#rid21">21</a>]. Other studies suggested benefit from parenteral anticoagulation for up to 14 days [<a href="#rid27">27-29</a>]. However, we do not recommend prolonged parenteral therapy, as early initiation of oral warfarin therapy in appropriate patients is likely to be as effective and is more practical.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>If indicated, oral anticoagulant therapy should be started early after MI and continued for at least three months, as most embolic events occur within the first three to four months. (See <a class="local">'Outcomes'</a> above.)</p><p></p><p>In patients who do not have a specific indication for <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> (eg, mechanical heart valve), we often prefer a DOAC due to convenience in dosing and more rapid achievement of therapeutic anticoagulation.</p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant antiplatelet therapy is indicated in all these patients, as they have sustained an MI. The use of combined anticoagulant and antiplatelet therapy is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy", section on 'Discharge to 12 months'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Our approach to the use of antiplatelet therapy after termination of anticoagulation is presented separately. (See  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy", section on 'Duration of dual antiplatelet therapy'</a>.)</p><p></p><p class="headingAnchor" id="H2333097876"><span class="h2">Evidence for anticoagulation</span><span class="headingEndMark"> — </span>The approach to prevention of stroke and systemic emboli in high-risk acute MI patients is based on limited evidence:</p><p class="bulletIndent1"><span class="glyph">●</span>Older, observational studies provide support for a recommendation to anticoagulate reperfused patients with <strong>documented LV thrombus</strong> after MI to reduce the risk of embolization [<a href="#rid7">7,21-23</a>]. There are no randomized trials evaluating the efficacy of prolonged oral anticoagulation, compared with no anticoagulation, in the present reperfusion era.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no studies that have compared anticoagulation with no anticoagulation in MI at-risk patients without LV thrombus. (See <a class="local">'At-risk patients'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There are no randomized studies that have compared <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> to DOAC for the prevention of thrombus formation in patients at high risk or for the treatment of LV thrombus. However, in case series of DOAC use in patients with documented LV thrombi, some with recent ST-elevation MI, DOAC use was associated with thrombus resolution [<a href="#rid30">30-34</a>] and was more effective than warfarin [<a href="#rid35">35</a>].</p><p></p><p class="bulletIndent1">One retrospective cohort study of 514 patients with echocardiographically detected LV thrombi included 300 who received <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> and 185 who received a DOAC [<a href="#rid36">36</a>]. After a median follow-up of nearly one year, anticoagulation with DOAC was associated with a higher risk of stroke or systemic embolism on multivariable analysis (hazard ratio 2.64, 95% CI 1.28-5.43).</p><p></p><p class="bulletIndent1">Based on this one study, we consider performing a follow-up TTE with an endocardial border definition agent after two to four weeks of DOAC to assess thrombus resolution. If there is no resolution, we consider switching to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>.</p><p></p><p class="headingAnchor" id="H2901931317"><span class="h2">Concomitant antiplatelet therapy</span><span class="headingEndMark"> — </span>All decisions regarding the prolonged use of anticoagulant therapy in these patients must take into account the concurrent risk of bleeding. Bleeding is a particularly important issue, as most of these patients have an indication for intense dual antiplatelet therapy (in addition to anticoagulant therapy) due to the placement of an intracoronary stent after an acute coronary syndrome. (See  <a class="medical medical_review" href="/z/d/html/95.html" rel="external">"Acute non-ST-elevation acute coronary syndromes: Early antiplatelet therapy", section on 'Summary and recommendations'</a> and  <a class="medical medical_review" href="/z/d/html/1572.html" rel="external">"Long-term antiplatelet therapy after coronary artery stenting in stable patients", section on 'Duration and Type of Antiplatelet Treatment'</a> and  <a class="medical medical_review" href="/z/d/html/1535.html" rel="external">"Coronary artery disease patients requiring combined anticoagulant and antiplatelet therapy"</a> and  <a class="medical medical_review" href="/z/d/html/94.html" rel="external">"Acute ST-elevation myocardial infarction: Antiplatelet therapy"</a>.)</p><p>While it is biologically plausible that intense antiplatelet therapy could protect against the formation and embolization of LV thrombus, this has not been studied, and we do not recommend it as a substitute for oral anticoagulation to prevent embolization of LV thrombus. Finally, there are no high-quality studies that address the issue of the optimal antithrombotic regimen in these patients with LV thrombus who are not stented. Specifically, the role of P2Y<sub>12</sub> receptor blockers has not been evaluated in randomized trials.</p><p class="headingAnchor" id="H2498677528"><span class="h1">ROLE OF FOLLOW-UP IMAGING</span><span class="headingEndMark"> — </span>TTE with contrast or long inversion time late gadolinium enhancement CMR imaging can be used to monitor resolution of thrombus with anticoagulation [<a href="#rid2">2,4,6,7,12</a>]. Most patients are followed by TTE, with CMR reserved only for situations in which TTE is technically suboptimal.</p><p>Based on a limited amount of evidence, we believe it is reasonable to get a follow-up TTE (if the thrombus was previously visualized on TTE) to determine if the thrombus identified on the first TTE has resolved or organized or to assess the degree of left ventricular (LV) remodeling. We obtain this follow-up TTE between two and three months after initial thrombus identification.</p><p>The findings of persistent pedunculation of the thrombus may reasonably lead to a decision to prolong anticoagulation beyond the recommended time; the finding of significant improvement of the LVEF and resolution of the apical wall motion abnormality may reasonably lead to a decision to shorten the duration of anticoagulation.</p><p>In three series in which serial TTE was performed, thrombus resolution was seen in 14 of 29 patients (47 percent) at six months, 24 of 51 (47 percent) at one year, and 16 of 21 (76 percent) at two-year follow-up [<a href="#rid4">4,6,12</a>]. As noted below, only a small number of late persistent thrombi are associated with embolic events, as most embolic events occur within the first four months. (See <a class="local">'Prevention of embolic events'</a> above.)</p><p>The predictors of LV thrombus resolution are not well defined. In one report, the only independent predictor of thrombus resolution was the absence of apical dyskinesis at six weeks after MI [<a href="#rid12">12</a>]. This observation is consistent with apical dyskinesis or akinesis being a risk factor for thrombus formation [<a href="#rid3">3</a>]. Although <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> therapy appears to reduce the rate of embolization, it may not increase the rate of thrombus resolution [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H1685330367"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113180.html" rel="external">"Society guideline links: ST-elevation myocardial infarction (STEMI)"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/114034.html" rel="external">"Society guideline links: Non-ST-elevation acute coronary syndromes (non-ST-elevation myocardial infarction)"</a>.)</p><p class="headingAnchor" id="H459652175"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathophysiology</strong> – Left ventricular (LV) thrombus is a major cause of embolic stroke after acute myocardial infarction (MI). Patients with large anterior MI are at the highest risk for the development of LV thrombi; these patients usually have an LV ejection fraction (LVEF) less than 30 percent and a severe anteroapical or basal inferolateral wall motion abnormality with aneurysm on an imaging study. (See <a class="local">'Pathophysiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – For patients at risk of LV thrombus, we obtain a transthoracic echocardiogram with echo contrast to screen for LV thrombus in those with an aneurysm. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Our recommendations for the use of anticoagulation are as follows:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Documented thrombus</strong> – For patients with MI and documented LV thrombus, we recommend anticoagulation (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Most of our contributors prefer direct-acting oral anticoagulants (DOAC; also referred to as non-vitamin K antagonist oral anticoagulants) to <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> for prophylaxis for LV thrombus. (See <a class="local">'Prevention of embolic events'</a> above.)</p><p></p><p class="bulletIndent2">In patients treated with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, parenteral anticoagulation with <a class="drug drug_general" data-topicid="8518" href="/z/d/drug information/8518.html" rel="external">unfractionated heparin</a> or low molecular weight heparin should be started as soon as possible and continued until effective oral anticoagulation has been achieved. Warfarin should be started soon after initiation of parenteral anticoagulation; the goal of therapy is an international normalized ratio of 2 to 3.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Low left ventricular ejection fraction</strong> – For patients with MI and no clear thrombus but an LVEF less than 30 with anteroapical or basal inferior/inferolateral wall akinesis/dyskinesis and aneurysm, we suggest prophylactic anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Prevention of embolic events'</a> above.)</p><p></p><p class="bulletIndent2">For patients with MI and an LVEF between 30 and 40 percent with a severe anteroapical hypokinesis on imaging but no dyskinesis or aneurysm or thrombus on imaging, we suggest not treating with prophylactic anticoagulation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>).</p><p></p><p class="bulletIndent2">The relative benefits and risks of anticoagulation need to be weighed carefully in these two groups.</p><p></p><p class="bulletIndent2">For those prescribed anticoagulation with <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a> or DOAC, we suggest continuing anticoagulation for three months rather than a longer duration (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We consider longer duration if there is residual thrombus after three months.</p><p></p><p class="headingAnchor" id="H815537847"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Scott Solomon, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Weinsaft JW, Kim J, Medicherla CB, et al. Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR. JACC Cardiovasc Imaging 2016; 9:505.</a></li><li><a class="nounderline abstract_t">Visser CA, Kan G, Meltzer RS, et al. Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients. J Am Coll Cardiol 1985; 5:1276.</a></li><li><a class="nounderline abstract_t">Asinger RW, Mikell FL, Elsperger J, Hodges M. Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography. N Engl J Med 1981; 305:297.</a></li><li><a class="nounderline abstract_t">Nihoyannopoulos P, Smith GC, Maseri A, Foale RA. The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity. J Am Coll Cardiol 1989; 14:903.</a></li><li><a class="nounderline abstract_t">Küpper AJ, Verheugt FW, Peels CH, et al. Left ventricular thrombus incidence and behavior studied by serial two-dimensional echocardiography in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism and oral anticoagulation. J Am Coll Cardiol 1989; 13:1514.</a></li><li><a class="nounderline abstract_t">Keren A, Goldberg S, Gottlieb S, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. J Am Coll Cardiol 1990; 15:790.</a></li><li><a class="nounderline abstract_t">Weinreich DJ, Burke JF, Pauletto FJ. Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography. Ann Intern Med 1984; 100:789.</a></li><li><a class="nounderline abstract_t">Vecchio C, Chiarella F, Lupi G, et al. Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study. Circulation 1991; 84:512.</a></li><li><a class="nounderline abstract_t">Chiarella F, Santoro E, Domenicucci S, et al. Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study. Am J Cardiol 1998; 81:822.</a></li><li><a class="nounderline abstract_t">Greaves SC, Zhi G, Lee RT, et al. Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction. Am J Cardiol 1997; 80:442.</a></li><li><a class="nounderline abstract_t">Nayak D, Aronow WS, Sukhija R, et al. Comparison of frequency of left ventricular thrombi in patients with anterior wall versus non-anterior wall acute myocardial infarction treated with antithrombotic and antiplatelet therapy with or without coronary revascularization. Am J Cardiol 2004; 93:1529.</a></li><li><a class="nounderline abstract_t">Nesković AN, Marinković J, Bojić M, Popović AD. Predictors of left ventricular thrombus formation and disappearance after anterior wall myocardial infarction. Eur Heart J 1998; 19:908.</a></li><li><a class="nounderline abstract_t">Rehan A, Kanwar M, Rosman H, et al. Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors. A prospective observational study. Cardiovasc Ultrasound 2006; 4:20.</a></li><li><a class="nounderline abstract_t">Gianstefani S, Douiri A, Delithanasis I, et al. Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention. Am J Cardiol 2014; 113:1111.</a></li><li><a class="nounderline abstract_t">Mansencal N, Nasr IA, Pillière R, et al. Usefulness of contrast echocardiography for assessment of left ventricular thrombus after acute myocardial infarction. Am J Cardiol 2007; 99:1667.</a></li><li><a class="nounderline abstract_t">Weinsaft JW, Kim RJ, Ross M, et al. Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus. JACC Cardiovasc Imaging 2009; 2:969.</a></li><li><a class="nounderline abstract_t">Srichai MB, Junor C, Rodriguez LL, et al. Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation. Am Heart J 2006; 152:75.</a></li><li><a class="nounderline abstract_t">Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation 2002; 106:2873.</a></li><li><a class="nounderline abstract_t">Barkhausen J, Hunold P, Eggebrecht H, et al. Detection and characterization of intracardiac thrombi on MR imaging. AJR Am J Roentgenol 2002; 179:1539.</a></li><li><a class="nounderline abstract_t">Stratton JR, Resnick AD. Increased embolic risk in patients with left ventricular thrombi. Circulation 1987; 75:1004.</a></li><li><a class="nounderline abstract_t">Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol 1993; 22:1004.</a></li><li><a class="nounderline abstract_t">Keating EC, Gross SA, Schlamowitz RA, et al. Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography. Am J Med 1983; 74:989.</a></li><li><a class="nounderline abstract_t">Cregler LL. Antithrombotic therapy in left ventricular thrombosis and systemic embolism. Am Heart J 1992; 123:1110.</a></li><li><a class="nounderline abstract_t">Meltzer RS, Visser CA, Fuster V. Intracardiac thrombi and systemic embolization. Ann Intern Med 1986; 104:689.</a></li><li><a class="nounderline abstract_t">Lattuca B, Bouziri N, Kerneis M, et al. Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus. J Am Coll Cardiol 2020; 75:1676.</a></li><li><a class="nounderline abstract_t">O'Gara PT, Kushner FG, Ascheim DD, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013; 127:e362.</a></li><li><a class="nounderline abstract_t">Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction. N Engl J Med 1989; 320:352.</a></li><li><a class="nounderline abstract_t">Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol 1997; 30:962.</a></li><li><a class="nounderline abstract_t">Heik SC, Kupper W, Hamm C, et al. Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk. J Am Coll Cardiol 1994; 24:1305.</a></li><li><a class="nounderline abstract_t">Cheong KI, Chuang WP, Wu YW, Huang SH. Successful Resolution of Left Ventricular Thrombus after ST-Elevation Myocardial Infarction by Edoxaban in a Patient with High Bleeding Risk. Acta Cardiol Sin 2019; 35:85.</a></li><li><a class="nounderline abstract_t">Shokr M, Ahmed A, Abubakar H, et al. Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature. Clin Case Rep 2019; 7:135.</a></li><li><a class="nounderline abstract_t">Bhatnagar UB, Rezkalla J, Sethi P, Stys A. Successful Resolution of a Large Left Ventricular Thrombus with Rivaroxaban Therapy after Acute Myocardial Infarction. S D Med 2018; 71:62.</a></li><li><a class="nounderline abstract_t">Bahmaid RA, Ammar S, Al-Subaie S, et al. Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review. JRSM Cardiovasc Dis 2019; 8:2048004019839548.</a></li><li><a class="nounderline abstract_t">Fleddermann A, Eckert R, Muskala P, et al. Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation. Am J Cardiol 2019; 123:57.</a></li><li><a class="nounderline abstract_t">Jones DA, Wright P, Alizadeh MA, et al. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. Eur Heart J Cardiovasc Pharmacother 2021; 7:398.</a></li><li><a class="nounderline abstract_t">Robinson AA, Trankle CR, Eubanks G, et al. Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi. JAMA Cardiol 2020; 5:685.</a></li></ol></div><div id="topicVersionRevision">Topic 90 Version 41.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26476503" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Echocardiographic Algorithm for Post-Myocardial Infarction LV Thrombus: A Gatekeeper for Thrombus Evaluation by Delayed Enhancement CMR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3998310" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Embolic potential of left ventricular thrombus after myocardial infarction: a two-dimensional echocardiographic study of 119 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7242633" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Incidence of left-ventricular thrombosis after acute transmural myocardial infarction. Serial evaluation by two-dimensional echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2794276" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The natural history of left ventricular thrombus in myocardial infarction: a rationale in support of masterly inactivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2723267" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Left ventricular thrombus incidence and behavior studied by serial two-dimensional echocardiography in acute anterior myocardial infarction: left ventricular wall motion, systemic embolism and oral anticoagulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2307788" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6721297" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Left ventricular mural thrombi complicating acute myocardial infarction. Long-term follow-up with serial echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1860196" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Left ventricular thrombus in anterior acute myocardial infarction after thrombolysis. A GISSI-2 connected study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9555769" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Predischarge two-dimensional echocardiographic evaluation of left ventricular thrombosis after acute myocardial infarction in the GISSI-3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9285655" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15194027" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Comparison of frequency of left ventricular thrombi in patients with anterior wall versus non-anterior wall acute myocardial infarction treated with antithrombotic and antiplatelet therapy with or without coronary revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9651715" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Predictors of left ventricular thrombus formation and disappearance after anterior wall myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16600036" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Incidence of post myocardial infarction left ventricular thrombus formation in the era of primary percutaneous intervention and glycoprotein IIb/IIIa inhibitors. A prospective observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24485697" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Incidence and predictors of early left ventricular thrombus after ST-elevation myocardial infarction in the contemporary era of primary percutaneous coronary intervention.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17560872" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Usefulness of contrast echocardiography for assessment of left ventricular thrombus after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19679285" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Contrast-enhanced anatomic imaging as compared to contrast-enhanced tissue characterization for detection of left ventricular thrombus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16824834" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Clinical, imaging, and pathological characteristics of left ventricular thrombus: a comparison of contrast-enhanced magnetic resonance imaging, transthoracic echocardiography, and transesophageal echocardiography with surgical or pathological validation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12460863" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12438051" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Detection and characterization of intracardiac thrombi on MR imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3568301" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased embolic risk in patients with left ventricular thrombi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8409034" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6859067" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mural thrombi in myocardial infarctions. Prospective evaluation by two-dimensional echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1553880" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Antithrombotic therapy in left ventricular thrombosis and systemic embolism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516044" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Intracardiac thrombi and systemic embolization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32273033" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Antithrombotic Therapy for Patients With Left Ventricular Mural Thrombus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23247304" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2643772" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombosis in patients with acute transmural anterior myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316525" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7930254" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Efficacy of high dose intravenous heparin for treatment of left ventricular thrombi with high embolic risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30713403" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Successful Resolution of Left Ventricular Thrombus after ST-Elevation Myocardial Infarction by Edoxaban in a Patient with High Bleeding Risk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30656027" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Use of direct oral anticoagulants in the treatment of left ventricular thrombi: A tertiary center experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29990412" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Successful Resolution of a Large Left Ventricular Thrombus with Rivaroxaban Therapy after Acute Myocardial Infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31007906" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Efficacy of direct oral anticoagulants on the resolution of left ventricular thrombus-A case series and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30376957" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32730627" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32320043" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Off-label Use of Direct Oral Anticoagulants Compared With Warfarin for Left Ventricular Thrombi.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
